Short Interest in Genmab A/S (NASDAQ:GMAB) Declines By 6.4%

Genmab A/S (NASDAQ:GMAB) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,620,000 shares, a decline of 6.4% from the January 15th total of 1,730,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is presently 1.2 days. Approximately 0.3% of the shares of the stock are short sold.

Genmab A/S Stock Up 2.2 %

Shares of GMAB opened at $21.77 on Wednesday. The firm has a market cap of $14.41 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 2.52 and a beta of 0.96. The company’s fifty day moving average is $20.64 and its two-hundred day moving average is $22.98. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities research analysts anticipate that Genmab A/S will post 1.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GMAB. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legacy Wealth Asset Management LLC lifted its holdings in shares of Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after acquiring an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after buying an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC lifted its position in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.